Genpact (G) Q3 2026 Earnings Call Transcript

Genpact reported Q3 2026 revenue of $1.385 billion, up 7.3% year over year, while Advanced Technology Solutions revenue grew 30.3% to $405 million and adjusted diluted EPS rose 10.3% to $1.07. Management raised full-year adjusted diluted EPS growth guidance to at least 13% and gross-margin guidance to 36.9%, and said 2026 agentic-solutions bookings will exceed $1 billion, more than five times 2025 bookings. Operating cash flow was $93 million after ERP-related invoicing and collection delays; management said collections had returned to their pre-implementation pace through October.

Analysis

The key underwriting question is conversion, not booking momentum. Agentic awards may support better revenue quality and lower labor intensity, but management says implementation takes longer; annualized contract value is not evidence that revenue or cash flow is already recurring at scale. In the next 1–3 months, watch ATS growth against the 25% full-year floor, backlog conversion, and receivables/DSO as the ERP billing disruption unwinds. A clean cash recovery would reduce liquidity concerns; renewed collection slippage would challenge the “temporary friction” explanation.

Over 6–18 months, the strategic mix could lift margins, but the transition has a near-term cost: management expects a larger dollar drag from exiting non-strategic work in 2027. Similar total growth guidance therefore does not yet establish accelerating consolidated growth. The reported gross-margin improvement is encouraging, while rising investment expense leaves the trade-off between reinvestment and operating leverage unresolved.

Contrarian point: the market may over-credit headline agentic bookings before implementation economics are demonstrated. Evidence to demand includes conversion into recognized revenue, renewal/expansion behavior, delivery effort per contract, and cash conversion—not just bookings or management’s characterization of annuitization. Genpact’s process expertise may differentiate it from large IT-services competitors such as Accenture, Infosys, and Cognizant, but those firms can also compete for transformation budgets. Nestlé’s selection of Genpact is a customer win, not evidence of a material consolidated impact for Nestlé.

Key Decisions for Investors

• Consider a modest long in Genpact (G) on weakness rather than chasing the earnings response; the thesis is ATS-led growth and improving mix, with upside dependent on bookings converting to revenue and margin. No valuation or post-earnings price data were supplied, so avoid a price target.
• Use ATS growth below the company’s 25% full-year expectation, weaker large-deal/backlog conversion, or a downward revision to 2027 growth as thesis-falsifying signals. Also monitor operating cash flow, receivables, and DSO over the next quarter; persistent collection weakness would undermine the ERP normalization case.
• Treat agentic bookings as a leading indicator, not near-term earnings. Reassess after the next 1–2 quarters for implementation pace, recognized revenue, and delivery economics; do not extrapolate the booking growth rate directly into EPS.